BRCA Testing and Targeting in EBC

CE / CME

Germline BRCA Testing and Targeting in HER2-Negative Early-Stage Breast Cancer

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurses: 0.50 Nursing contact hour

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: May 07, 2024

Expiration: May 06, 2025

Activity

Progress
1 2
Course Completed

References

  1. Kim HJ, Kim S, Freedman RA, et al. The impact of young age at diagnosis (age <40 years) on prognosis varies by breast cancer subtype: A U.S. SEER database analysis. Breast. 2022;61:77-83.
  2. Geyer CE Jr, Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33:1250-1268.
  3. Rastogi P, O'Shaughnessy J, Martin M, et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. J Clin Oncol. 2024;42:987-993.
  4. Tung N, Lin NU, Kidd J, et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol. 2016;34:1460-1468.
  5. Winter C, Nilsson MP, Olsson E, et al. Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic. Ann Oncol. 2016;27:1532-1538.
  6. Couch FJ, Hart SN, Sharma P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015;33:304-311.
  7. Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17:1082-1089.
  8. Engel C, Rhiem K, Hahnen E, et al. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history. BMC Cancer. 2018;18:265.
  9. Sharma P, Klemp JR, Kimler BF, et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat. 2014;145:707-714.
  10. Greenup R, Buchanan A, Lorizio W, et al. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann Surg Oncol. 2013;20:3254-3258.
  11. Rose M, Burgess JT, O’Byrne K, et al. PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance. Front Cell Dev Biol. 2020;8:564601.
  12. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917-921.
  13. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008;26:3785-3790.
  14. Turk AA, Wisinski KB. PARP inhibitors in breast cancer: bringing synthetic lethality to the bedside. Cancer. 2018;124:2498-2506.
  15. Olaparib [prescribing information]. Gaithersburg, MD: AstraZeneca Pharmaceuticals LP; 2023.
  16. Talazoparib [prescribing information]. New York, NY: Pfizer, Inc.; 2024.
  17. Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384:2394-2405.
  18. Mittendorf EA, Jeruss JS, Tucker SL, et al. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol. 2011;29:1956-1962.
  19. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast, ovarian, and pancreatic. v.3.2024. nccn.org. Accessed May 3, 2024.
  20. National Cancer Institute. BRCA gene mutations: cancer risk and genetic testing. cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet#does-health-insurance-cover-the-cost-of-genetic-testing-for-brca1-and-brca2-variants. Accessed May 3, 2024.
  21. Robson M. Testing for inherited susceptibility to breast cancer. Hematol Oncol Clin North Am. 2023;37:17-31.
  22. Tung NM, Robson ME, Ventz S, et al. TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J Clin Oncol. 2020;38:4274-4282.
  23. LaFargue CJ, Dal Molin GZ, Sood AK, et al. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019;20:e15-e28.
  24. Tew WP, Lacchetti C, Ellis A, et al. PARP inhibitors in the management of ovarian cancer: ASCO guideline. J Clin Oncol. 2020;38:3468-3493.
  25. Morice PM, Leary A, Dolladille C, et al. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematol. 2021;8:e122-e134.
  26. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: antiemesis. v.1.2024. nccn.org. Accessed May 3, 2024.
  27. Capelli D, Menotti D, Fiorentini A, et al. Chapter 7: secondary acute myeloid leukemia: pathogenesis and treatment. Leukemia [Internet]. ncbi.nlm.nih.gov/books/NBK586211/. Accessed May 3, 2024.
  28. Lambourne T, Minard LV, Deal H, et al. Optimizing patient education of oncology medications: a patient perspective. J Cancer Educ. 2019;34:1024-1030.
  29. Schneider SM, Hess K, Gosselin T. Interventions to promote adherence with oral agents. Semin Oncol Nurs. 2011;27:133-141.
  30. Zettler CM, De Silva DL, Blinder VS, et al. Cost-effectiveness of adjuvant olaparib for patients with breast cancer and germline BRCA1/2 mutations. JAMA Netw Open. 2024;7:e2350067.
  31. Knight TG, Deal AM, Dusetzina SB, et al. Financial toxicity in adults with cancer: adverse outcomes and noncompliance. J Oncol Pract. 2018;14:e665-e673.